
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is expected to have strong total revenue growth in the coming years, with estimated total revenue of $46,990M, $45,614M, and $40,649M for 2026, 2027, and 2028, respectively. This is driven by their strong focus on immuno-oncology, where they are a leader in drug development, and their continued success in the US market, which accounts for 70% of their total sales. Additionally, the increase in their price target is supported by an increasing exit multiple in their DCF analysis, showing potential for strong future financial performance.
Bears say
Bristol-Myers Squibb is heavily dependent on the US market, which poses a risk of revenue concentration. There is potential for transformative clinical readouts in various therapeutic areas, but there are still fundamental risks such as increased competition and potential for delays in clinical trials. The company's recent guidance updates show conservative sales growth for their popular drug Eliquis and increased PoS for their other drugs, resulting in a higher price target of $72/share.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares